Outcome prediction in sepsis combined use of genetic polymorphisms - A study in Japanese population

Cytokine

Volumn 54, Issue 1, 2011, Pages 79-84

  Shimada, Tadanaga ^a   Oda, Shigeto ^a   Sadahiro, Tomohito ^a   Nakamura, Masataka ^a   Hirayama, Yoh ^a   Watanabe, Eizo ^a   Abe, Ryuzo ^a   Nakada, Taka aki ^a   Tateishi, Yoshihisa ^a   Otani, Shunsuke ^a   Hirasawa, Hiroyuki ^a   Tokuhisa, Takeshi ^a   Uno, Hajime ^b  

^a CHIBA UNIVERSITY   (Japan)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Genetics; Interleukin 1; Risk factors; Sepsis; Tumor necrosis factor

Indexed keywords

ALANINE; CD14 ANTIGEN; CYSTEINE; GLYCINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN C; THREONINE; TUMOR NECROSIS FACTOR;

ACCURACY; ADULT; AGED; APACHE; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE UNIT; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; APACHE; AREA UNDER CURVE; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; JAPAN; MALE; MIDDLE AGED; MODELS, GENETIC; POLYMORPHISM, GENETIC; ROC CURVE; SEPSIS; TREATMENT OUTCOME;

EID: 79952073447     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.12.001     Document Type: Article

References (35)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
2. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
3. Arcaroli J., Fessler M.B., Abraham E. Genetic polymorphisms and sepsis. Shock 2005, 24:300-312.
4. Barber R.C., Chang L.Y., Lemaire S.M., Burris A., Purdue G.F., Hunt J.L., et al. Epistatic interactions are critical to gene-association studies: PAI-1 and risk for mortality after burn injury. J Burn Care Res 2008, 29:168-175.
5. Zhai R., Zhou W., Gong M.N., Thompson B.T., Su L., Yu C., et al. Inhibitor κB-α haplotype GTC is associated with susceptibility to acute respiratory distress syndrome in Caucasians. Crit Care Med 2007, 35:893-898.
6. Calvano J.E., Um J.Y., Agnese D.M., Hahm S.J., Kumar A., Coyle S.M., et al. Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients. Surg Infect 2003, 4:163-169.
7. Christie J.D. The interleukin-6 gene and critical illness: is inflammatory gene variation the key to personalized medicine in the intensive care unit?. Crit Care Med 2008, 36:1647-1649.
8. Nakada T.A., Hirasawa H., Oda S., Shiga H., Matsuda K., Nakamura M., et al. Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukine-10 gene polymorphisms on clinical outcome in Japanese critically ill patients. J Surg Res 2005, 129:322-328.
9. Watanabe E., Hirasawa H., Oda S., Matsuda K., Nakamura M., Abe R., et al. Cytokine-related genotypic differences in peak interleukin-6 blood levels of patients with SIRS and septic complications. J Trauma 2005, 59:1181-1189.
10. Watanabe E., Hirasawa H., Oda S., Matsuda K., Hatano M., Tokuhisa T. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 2005, 33:89-97.
11. Kraus W.A., Draper E.A., Wagner D., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
12. Mannino D.M., Buist A.S., Petty T.L., Enright P.L., Redd S.C. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003, 58:388-393.
13. Egi M., Bellomo R., Stachowski E., French C.J., Hart G.K., Hegarty C., et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med 2008, 36:2249-2255.
14. Mostafa G., Huynh T., Sing R.F., Miles W.S., Norton H.J., Thomason M.H. Gender-related outcomes in trauma. J Trauma 2002, 53:430-434.
15. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Sepsis occurrence in acutely Ill patients investigators: sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
16. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256.
17. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
18. Ma P., Chen D., Pan J., Du B. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002, 30:1046-1050.
19. Oda S., Hirasawa H., Shiga H., Nakanishi K., Matsuda K., Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005, 29:169-175.
20. R Development Core Team R: a language and environment for statistical computing 2007, R Foundation for Statistical Computing, Vienna, Austria.
21. Watanabe E., Buchman T.G., Hirasawa H., Zehnbauer B.A. Association between lymphotoxin-alpha (tumor necrosis factor-beta) intron polymorphism and predisposition to severe sepsis is modified by gender and age. Crit Care Med 2010, 38:181-193.
22. Sablotzki A., Dehne M.G., Friedrich I., Grond S., Zickmann B., Mühling J., et al. Different expression of cytokines in survivors and non-survivors from MODS following cardiovascular surgery. Eur J Med Res 2003, 8:71-76.
23. Vianna R.C., Gomes R.N., Bozza F.A., Amancio R.T., Bozza P.T., David C.M., et al. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 2004, 21:115-120.
24. Turnbull I.R., Javadi P., Buchman T.G., Hotchkiss R.S., Karl I.E., Coopersmith C.M. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 2004, 21:121-125.
25. Teuffel O., Ethier M.C., Beyene J., Sung L. Association between tumor necrosis factor-alpha promoter -308A/G polymorphism and susceptibility to sepsis and sepsis mortality: a systematic review and meta-analysis. Crit Care Med 2010, 38:276-282.
26. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
27. Louis E., Franchimont D., Piron A., Gevaert Y., Schaaf-Lafontaine N., Roland S., et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998, 113:401-406.
28. Kovar F.M., Marsik C., Cvitko T., Wagner O.F., Jilma B., Endler G. The tumor necrosis factor alpha -308G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock 2007, 27:238-241.
29. Stuber F., Udalova I.A., Book M., Drutskaya L.N., Kuprash D.V., Turetskaya R.L., et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1995, 46:42-50.
30. Menges T., König I.R., Hossain H., Little S., Tchatalbachev S., Thierer F., et al. Sepsis syndrome and death in trauma patients are associated with variation in the gene encoding tumor necrosis factor. Crit Care Med 2008, 36:1456-1462.
31. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Young H.A., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
32. Barber R.C., Chang L.Y., Arnoldo B.D., Purdue G.F., Hunt J.L., Horton J.W., et al. Innate immunity SNPs are associated with risk for severe sepsis after burn injury. Clin Med Res 2006, 4:250-255.
33. Kumpf O., Hamann L., Schlag P.M., Schumann R.R. Pre- and postoperative cytokine release after in vitro whole blood lipopolysaccharide stimulation and frequent toll-like receptor 4 polymorphisms. Shock 2006, 25:123-128.
34. García-Segarra G., Espinosa G., Tassies D., Oriola J., Aibar J., Bové A., et al. Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med 2007, 33:1354-1362.
35. Manocha S., Russell J.A., Sutherland A.M., Wattanathum A., Walley K.R. Fibrinogen-beta gene haplotype is associated with mortality in sepsis. J Infect 2007, 54:572-577.